PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients

PURPOSE: To assess efficacy and safety of palbociclib plus fulvestrant in Asians with endocrine therapy–resistant metastatic breast cancer. PATIENTS AND METHODS: The Palbociclib Ongoing Trials in the Management of Breast Cancer 3 (PALOMA-3) trial, a double-blind phase III study, included 521 patient...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Glob Oncol
Huvudupphovsmän: Iwata, Hiroji, Im, Seock-Ah, Masuda, Norikazu, Im, Young-Hyuck, Inoue, Kenichi, Rai, Yoshiaki, Nakamura, Rikiya, Kim, Jee Hyun, Hoffman, Justin T., Zhang, Ke, Giorgetti, Carla, Iyer, Shrividya, Schnell, Patrick T., Bartlett, Cynthia Huang, Ro, Jungsil
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Clinical Oncology 2017
Ämnen:
ORIGINAL REPORTS
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5560465/
https://ncbi.nlm.nih.gov/pubmed/28831437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JGO.2016.008318
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk